BUTORPHANOL TARTRATE injection

Nchi: Marekani

Lugha: Kiingereza

Chanzo: NLM (National Library of Medicine)

Viambatanisho vya kazi:

BUTORPHANOL TARTRATE (UNII: 2L7I72RUHN) (BUTORPHANOL - UNII:QV897JC36D)

Inapatikana kutoka:

Bayer HealthCare LLC, Animal Health Division

INN (Jina la Kimataifa):

BUTORPHANOL TARTRATE

Tungo:

BUTORPHANOL TARTRATE 10 mg in 1 mL

Njia ya uendeshaji:

INTRAVENOUS

Dawa ya aina:

PRESCRIPTION

Matibabu dalili:

Butorphanol Tartrate Injection is indicated for the relief of pain associated with colic in adult horses and yearlings. Clinical studies in the horse have shown that Butorphanol Tartrate Injection alleviates abdominal pain associated with torsion, impaction, intussusception, spasmodic and tympanic colic and postpartum pain.

Bidhaa muhtasari:

50 mL vials Butorphanol Tartrate Injection. 10 mg base activity per mL. Store at controlled room temperature 20°-25°C (68°-77°F).

Idhini hali ya:

Abbreviated New Animal Drug Application

Tabia za bidhaa

BUTORPHANOL TARTRATE- BUTORPHANOL TARTRATE INJECTION
BAYER HEALTHCARE LLC, ANIMAL HEALTH DIVISION
----------
ANADA 200-322, APPROVED BY FDA
BUTORPHANOL TARTRATE INJECTION
CIV
CAUTION
Federal law restricts this drug to use by or on the order of a
licensed veterinarian.
DESCRIPTION
Butorphanol Tartrate Injection is a totally synthetic, centrally
acting, narcotic agonist-
antagonist analgesic with potent antitussive activity. It is a member
of the phenanthrene
series. The chemical name is Morphinan-3, 14-diol,
17-(cyclobutylmethyl)-, (-)-, (S- (R*,
R*))-2, 3-dihydroxybutanedioate (1:1) (salt). It is a white,
crystalline, water soluble
substance having a molecular weight of 477.55; its molecular formula
is
C
H
NO2.C H O .
Each mL of Butorphanol Tartrate Injection contains 10 mg butorphanol
base (as
butorphanol tartrate), 3.3 mg citric acid, 6.4 mg sodium citrate, 4.7
mg sodium chloride,
and 0.1 mg benzethonium chloride, q.s. with water for injection.
CLINICAL PHARMACOLOGY
COMPARATIVE PHARMACOLOGY
In animals, butorphanol has been demonstrated to be 4 to 30 times more
potent than
morphine and pentazocine (Talwin -V) respectively.
In humans, butorphanol has been
shown to have 5-7 times the analgesic activity of morphine and 20
times that of
pentazocine.
Butorphanol has 15 to 20 times the oral antitussive activity of
codeine or
dextromethorphan in dogs and guinea pigs.
As an antagonist, butorphanol is approximately equivalent to
nalorphine and 30 times
21
29
4
6
6
®
1
2,3
4
1
more potent than pentazocine.
Cardiopulmonary depressant effects are minimal after treatment with
butorphanol as
demonstrated in dogs , humans
and horses.
Unlike classical narcotic agonist
analgesics which are associated with decreases in blood pressure,
reduction in heart
rate and concomitant release of histamine, butorphanol does not cause
histamine
release.
Furthermore, the cardiopulmonary effects of butorphanol are not
distinctly
dosage-related but rather reach a ceiling effect beyond which further
dosage increases
result in relatively lesser e